Plasminogen Market Size, Share & Industry Analysis, By Product Type (Plasminogen Concentrate, Recombinant Plasminogen, and Plasminogen Activators), By Application (Plasminogen Deficiency Type 1, Thrombolytic Therapy, and Others), By Route of Administration (Intravenous and Others), By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, and Others), and Regional Forecast, 2026-2034

The global plasminogen market size was valued at USD 1.89 billion in 2024 and is projected to reach USD 2.67 billion by 2032, exhibiting a CAGR of 4.01% during the forecast period. The market is expected to grow significantly owing to the criticality of plasminogen for clot resolution, wound healing, and tissue remodeling. It is a vital precursor of plasmin, which is responsible for breaking down fibrin clots. 

Furthermore, increasing plasminogen deficiency and disorders, such as deep vein thrombosis (DVT), pulmonary embolism, and stroke, are likely to boost the demand for plasminogen therapy, driving the market growth.

• For instance, as per World Stroke Organization, over 12.2 million of new stroke cases are registered every year.

Plasminogen Market Driver

Rising Incidence of Thrombotic Disorders to Boost the Market Growth

The global increase of thrombolytic diseases and cardiovascular conditions are poised to drive the demand for plasminogen and boost the market growth.

• For instance, in December 2024, as per data published by National Institute of Health, the incidence of acute pulmonary embolism ranges from 39 to 115 per 100,000 population annually.

Download Free sample to learn more about this report.

According to the Global Burden of Disease (GBD) 2021, the stroke burden was estimated to be around 93.8 million cases.

Plasminogen Market Restraint

Limited Geographic Availability of Human Plasminogen Concentrate to Hamper the Market Growth

The limited approval of Ryplazim, exclusively only within the U.S., is likely to create hurdles in the expansion and adoption of these products in different geographic areas.

• For instance, as per the European Parliamentary in October 2024, the adoption of Ryplazim has not yet been authorized by the European Medicines Agency (EMA).

Furthermore, the absence of established reimbursement pathways for ultra-rare therapies in many regions further limits its potential market growth.

Plasminogen Market Opportunity

Development of Recombinant Plasminogen Products to Offer Lucrative Growth Opportunity

The limited availability of plasma for fractionation and issues associated with viral safety and allergic reactions in patients, shifted the focus toward development of recombinant plasminogen. The development of recombinant plasminogen is expected to limit the issues associated with the human plasma derived plasminogen, offering lucrative opportunities for market expansion.

• For instance, in May 2023, Omnio AB, a biopharmaceutical company, announced results from preclinical wound studies involving recombinant plasminogen.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Key Countries/ Regions, 2024
• Key Industry Developments (Mergers, Acquisitions, Collaborations, and Others)
• Pipeline Analysis
• Technological Advancements in the Market
• Regulatory & Reimbursement Scenario, By Key Countries/ Regions
• Economic Cost Burden for the Treatment of Key Diseases

Analysis by Product Type

Based on product type, the market is fragmented into plasminogen concentrate, recombinant plasminogen, and plasminogen activators.

The plasminogen activators segment dominated the market. The dominant share is due to the increasing prevalence of stroke and thrombolytic diseases and regulatory approval for new plasminogen activators.

• For instance, in March 2025, Genentech announced the U.S. Food and Drug Administration (FDA) approval for TNKase (tenecteplase), a thrombolytic or clot-dissolving agent for the treatment of acute ischemic stroke (AIS) in adults.

Analysis by Application

The market, by application, has been studied across plasminogen deficiency type 1, thrombolytic therapy, and others.

The thrombolytic therapy segment held a significant market share. The significant share is attributed to the high-incidence of acute ischemic stroke, myocardial infarction, and pulmonary embolism. Further, the widespread hospital use of plasminogen activators to boost the segment’s growth.

• For instance, in April 2023, as per the BMC Cardiovascular Disorders report, more than 3 million individuals develop ST-elevation myocardial infarction (STE-MI) each year.

Analysis by Route of Administration

On the basis of route of administration, the market is bifurcated into intravenous and others.

The intravenous segment held a significant market share. The dominant share is attributed to the presence of most therapeutic products, such as plasminogen concentrates, recombinant, or plasminogen activators, which are formulated for IV infusion. IV administration is important for emergency situations such as stroke, myocardial infarction, and others. The new product launches and approvals in IV formulation are poised to propel the segment’s growth in the market.

• For instance, in August 2025, a research study performed at Zhejiang University School of Medicine (SAHZU) unveiled that administering intravenous alteplase within 4.5 to 24 hours after stroke onset can offer functional benefits to acute ischemic stroke patients with salvageable brain tissue.

Analysis by Distribution Channel

Based on the distribution channel, the market is subdivided into hospital pharmacy, specialty pharmacy, and others.

The hospital pharmacy segment held the maximum market share. An increasing demand for plasminogen in emergency situations and administered under medical supervision, is propelling the distribution from these channels, eventually propelling segment growth.

• For instance, in June 2025, under the Andhra Pradesh India STEMI (ST-elevated myocardial infarction) program, around 2,650 lives were saved from heart attack by using Tenecteplase injections.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market, in terms of region, has been analyzed across North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa.

North America accounted for a dominant share of the global plasminogen market in 2024, accounting for a market share of 47%. The presence of strong regulatory support, advanced plasma fractionation facilities. Further, the region has strong focus on offering reimbursement coverage for critical treatments, bolstering the growth of the market.

• For instance, in March 2025, Kedrion broadened its distribution network for Ryplazim, with an aim to ensure that patients across the U.S. have timely access to this essential medication.

The Europe market is witnessing steady growth during forecast period. The increasing awareness of congenital plasminogen deficiency and broader hospital adoption of thrombolytic drugs is further expected to propel the regional market growth.

• For instance, in November 2024, according to data published by NHS England, stroke admissions in England have risen to 111,137 in 2023/24, up from 87,069 in 2004/05 due to rising aging population and the influence of lifestyle factors.

Moreover, the Asia Pacific is expected to grow at a significant CAGR during the forecast period. The increasing incidence of thrombotic disorders, and rising government initiatives to improve access to thrombolytic therapies is expected to boost the market's growth in the Asia Pacific region.

Key Players Covered

The global plasminogen market is highly consolidated, with few major standalone providers.

The report includes the profiles of the following key players:

• CSL (Australia)
• Sanofi (France)
• Genentech (U.S.)
• Grifols S.A.(Spain)
• Kedrion (Italy)
• Sandoz (Switzerland)

Key Industry Developments

• June 2021: Kedrion announced the U.S. FDA approval for Ryplazim (plasminogen) first intravenous plasminogen concentrate for treating congenital plasminogen deficiency Type 1.
• November 2020: Liminal BioSciences Inc. announced that the U.S. Food and Drug Administration (FDA) extension in the review period for its Biologics License Application (BLA) for Ryplazim (plasminogen).